🎉 M&A multiples are live!
Check it out!

PolyPeptide Valuation Multiples

Discover revenue and EBITDA valuation multiples for PolyPeptide and similar public comparables like Syngene International, Dishman Carbogen Amics, and Biocon.

PolyPeptide Overview

About PolyPeptide

PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.


Founded

1952

HQ

Switzerland
Employees

1.3K+

Website

polypeptide.com

Financials

LTM Revenue $365M

LTM EBITDA $34.4M

EV

$585M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

PolyPeptide Financials

PolyPeptide has a last 12-month revenue of $365M and a last 12-month EBITDA of $34.4M.

In the most recent fiscal year, PolyPeptide achieved revenue of $383M and an EBITDA of $32.1M.

PolyPeptide expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See PolyPeptide valuation multiples based on analyst estimates

PolyPeptide P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $5.0M $383M XXX XXX XXX
Gross Profit -$256M -$352M XXX XXX XXX
Gross Margin -5153% -92% XXX XXX XXX
EBITDA -$25.0M $32.1M XXX XXX XXX
EBITDA Margin -504% 8% XXX XXX XXX
Net Profit $8.8M -$58.2M XXX XXX XXX
Net Margin 177% -15% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

PolyPeptide Stock Performance

As of April 15, 2025, PolyPeptide's stock price is CHF 15 (or $17).

PolyPeptide has current market cap of CHF 493M (or $557M), and EV of CHF 517M (or $585M).

See PolyPeptide trading valuation data

PolyPeptide Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$585M $557M XXX XXX XXX XXX $-0.41

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

PolyPeptide Valuation Multiples

As of April 15, 2025, PolyPeptide has market cap of $557M and EV of $585M.

PolyPeptide's trades at 1.5x LTM EV/Revenue multiple, and 16.2x LTM EBITDA.

Analysts estimate PolyPeptide's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for PolyPeptide and 10K+ public comps

PolyPeptide Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $585M XXX XXX XXX
EV/Revenue 1.5x XXX XXX XXX
EV/EBITDA 18.2x XXX XXX XXX
P/E -25.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 212.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get PolyPeptide Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

PolyPeptide Valuation Multiples

PolyPeptide's NTM/LTM revenue growth is 16%

PolyPeptide's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $40K for the same period.

Over next 12 months, PolyPeptide's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate PolyPeptide's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for PolyPeptide and other 10K+ public comps

PolyPeptide Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 7599% XXX XXX XXX XXX
EBITDA Margin 8% XXX XXX XXX XXX
EBITDA Growth -228% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 25% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $40K XXX XXX XXX XXX
S&M Expenses to Revenue 0% XXX XXX XXX XXX
G&A Expenses to Revenue 6% XXX XXX XXX XXX
R&D Expenses to Revenue 0% XXX XXX XXX XXX
Opex to Revenue 13% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

PolyPeptide Public Comps

See public comps and valuation multiples for Contract Research & Manufacturing and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Jubilant Pharmova XXX XXX XXX XXX XXX XXX
Biocon XXX XXX XXX XXX XXX XXX
Syngene International XXX XXX XXX XXX XXX XXX
Dishman Carbogen Amics XXX XXX XXX XXX XXX XXX
Suven Pharma XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

PolyPeptide M&A and Investment Activity

PolyPeptide acquired  XXX companies to date.

Last acquisition by PolyPeptide was  XXXXXXXX, XXXXX XXXXX XXXXXX . PolyPeptide acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by PolyPeptide

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About PolyPeptide

When was PolyPeptide founded? PolyPeptide was founded in 1952.
Where is PolyPeptide headquartered? PolyPeptide is headquartered in Switzerland.
How many employees does PolyPeptide have? As of today, PolyPeptide has 1.3K+ employees.
Is PolyPeptide publicy listed? Yes, PolyPeptide is a public company listed on SWX.
What is the stock symbol of PolyPeptide? PolyPeptide trades under PPGN ticker.
When did PolyPeptide go public? PolyPeptide went public in 2021.
Who are competitors of PolyPeptide? Similar companies to PolyPeptide include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics.
What is the current market cap of PolyPeptide? PolyPeptide's current market cap is $557M
What is the current revenue of PolyPeptide? PolyPeptide's last 12-month revenue is $365M.
What is the current EBITDA of PolyPeptide? PolyPeptide's last 12-month EBITDA is $34.4M.
What is the current EV/Revenue multiple of PolyPeptide? Current revenue multiple of PolyPeptide is 1.5x.
What is the current EV/EBITDA multiple of PolyPeptide? Current EBITDA multiple of PolyPeptide is 16.2x.
What is the current revenue growth of PolyPeptide? PolyPeptide revenue growth between 2023 and 2024 was 7599%.
Is PolyPeptide profitable? Yes, PolyPeptide is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.